JP6856648B2 - Ｃｘｃｒ４受容体アンタゴニスト - Google Patents

Ｃｘｃｒ４受容体アンタゴニスト Download PDF

Info

Publication number
JP6856648B2
JP6856648B2 JP2018531058A JP2018531058A JP6856648B2 JP 6856648 B2 JP6856648 B2 JP 6856648B2 JP 2018531058 A JP2018531058 A JP 2018531058A JP 2018531058 A JP2018531058 A JP 2018531058A JP 6856648 B2 JP6856648 B2 JP 6856648B2
Authority
JP
Japan
Prior art keywords
methyl
alkyl
pyrimidin
imidazole
tetrahydroquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018531058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019502680A5 (enExample
JP2019502680A (ja
Inventor
グレッチェン・エム・シュローダー
トラム・エヌ・ハイン
ハイディ・エル・ペレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019502680A publication Critical patent/JP2019502680A/ja
Publication of JP2019502680A5 publication Critical patent/JP2019502680A5/ja
Application granted granted Critical
Publication of JP6856648B2 publication Critical patent/JP6856648B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2018531058A 2015-12-15 2016-12-14 Ｃｘｃｒ４受容体アンタゴニスト Active JP6856648B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267649P 2015-12-15 2015-12-15
US62/267,649 2015-12-15
PCT/US2016/066575 WO2017106291A1 (en) 2015-12-15 2016-12-14 Cxcr4 receptor antagonists

Publications (3)

Publication Number Publication Date
JP2019502680A JP2019502680A (ja) 2019-01-31
JP2019502680A5 JP2019502680A5 (enExample) 2020-01-23
JP6856648B2 true JP6856648B2 (ja) 2021-04-07

Family

ID=57755467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018531058A Active JP6856648B2 (ja) 2015-12-15 2016-12-14 Ｃｘｃｒ４受容体アンタゴニスト

Country Status (6)

Country Link
US (1) US10450318B2 (enExample)
EP (1) EP3390406A1 (enExample)
JP (1) JP6856648B2 (enExample)
KR (1) KR102738306B1 (enExample)
CN (1) CN108602829A (enExample)
WO (1) WO2017106291A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11497744B2 (en) 2017-02-21 2022-11-15 Emory University Chemokine CXCR4 receptor modulators and uses related thereto
CN109553604B (zh) * 2017-09-25 2021-08-27 盛世泰科生物医药技术(苏州)有限公司 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
EP3768256A4 (en) 2018-03-19 2021-11-24 Emory University PAN-TROPICAL ENTRANCE INHIBITORS
WO2023003862A1 (en) 2021-07-19 2023-01-26 Emory University Cxcr4 modulators and uses related thereto
CN115403510B (zh) * 2022-08-11 2023-04-25 南方医科大学 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127547D0 (en) * 2001-11-16 2002-01-09 Astrazeneca Ab Chemical compounds
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
EP1799671A4 (en) * 2004-09-02 2009-06-10 Smithkline Beecham Corp CHEMICAL COMPOUNDS
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
WO2006076131A2 (en) 2004-12-17 2006-07-20 Smithkline Beecham Corporation Chemical compounds
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CA2616196C (en) 2005-07-22 2012-08-21 Eli Lilly And Company A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
AR059197A1 (es) * 2006-01-25 2008-03-19 Smithkline Beecham Corp Derivados de indazolo piridina para el tratamiento de hiv
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
AU2008353145B2 (en) 2008-01-03 2013-09-12 Universite D' Aix-Marseille Bitherapy and tritherapy used for treating an HIV-positive patient
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
IN2015DN02826A (enExample) 2009-09-03 2015-09-11 Merck Sharp & Dohme
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
NO2694640T3 (enExample) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法

Also Published As

Publication number Publication date
CN108602829A (zh) 2018-09-28
US10450318B2 (en) 2019-10-22
US20180327409A1 (en) 2018-11-15
EP3390406A1 (en) 2018-10-24
JP2019502680A (ja) 2019-01-31
KR102738306B1 (ko) 2024-12-03
KR20180094036A (ko) 2018-08-22
WO2017106291A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
CA2961740C (en) N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors
JP7254821B2 (ja) 抗がん剤としての環状ジヌクレオチド
JP6639497B2 (ja) ブロモドメインインヒビターおよびその使用
TWI866258B (zh) 用於治療發炎性病症之新穎化合物及其醫藥組合物
KR20250113487A (ko) 화합물
US9708316B2 (en) TGFβR antagonists
JP2021519308A (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤
WO2017117474A1 (en) Bifunctional compounds for her3 degradation and methods of use
JP2019516759A (ja) がんの処置のためのピラゾロピリジン誘導体
AU2017290748A1 (en) Pyrimidine-based antiproliferative agents
US20200283406A1 (en) Antiproliferative pyrimidine-based compounds
WO2017117473A1 (en) Bifunctional molescules for her3 degradation and methods of use
JP2022511112A (ja) Ａｌｋ５阻害剤としてのナフチリジンおよびキノリン誘導体
JP2017533248A (ja) ブロモドメインのインヒビターとしての置換ピロロピリジン
TW200908983A (en) Heterocyclic compounds and uses thereof
EP3256450B1 (en) Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof
TW201718546A (zh) 適用作pim激酶抑制劑之雜環化合物
KR102738306B1 (ko) Cxcr4 수용체 길항제
JP2021513562A (ja) 抗がん剤としての環状ジヌクレオチド
WO2016198908A1 (en) Ror nuclear receptor modulators
JP2018528951A (ja) ＴＧＦβ受容体アンタゴニスト
JP2018525415A (ja) Ｔｇｆベータ受容体アンタゴニスト
US20130184273A1 (en) Bicyclic pyrimidines
CA3238595A1 (en) 15-pgdh inhibitor and use thereof
JP2018526344A (ja) Ｔｇｆベータ受容体アンタゴニスト

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210309

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210318

R150 Certificate of patent or registration of utility model

Ref document number: 6856648

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250